ALLMedicine™ Osteogenesis Imperfecta Center

Mar 17th, 2023 - This protocol seeks to formalize the application of accepted diagnostic and therapeutic measures in the study of individuals with known or suspected bone-related connective tissue disorders, including Osteogenesis Imperfecta and melorheostosis. It...

Mar 17th, 2023 - Osteogenesis imperfecta (OI) is associated with short stature, which is mild, severe and moderate in OI types I, III and IV, respectively. Standardized OI type- and sex-specific growth charts across all pediatric ages do not exist. We assessed 573...

Mar 12th, 2023 - Clinical-functional assessment of patients affected by Osteogenesis Imperfecta and Ehlers-Danlos Syndromes is essential for clinical management. However, there is no clear information on disease-specific tools of assessment for clinical practice, ...

Mar 11th, 2023 - Pathogenic variants in COL1A1 and COL1A2 are involved in osteogenesis imperfecta (OI) and, rarely, Ehlers-Danlos syndrome (EDS) subtypes and OI-EDS overlap syndromes (OIEDS1 and OIEDS2, respectively). Here we describe a cohort of 34 individuals wi...

Mar 9th, 2023 - The primary objective of this study is to evaluate the pharmacokinetics (PK) profile following multiple subcutaneous (SC) doses of romosozumab in children and adolescents with Osteogenesis Imperfecta (OI).

Jan 15th, 2023 - Pulmonary involvement in Osteogenesis Imperfecta (OI) can be severe but may be overlooked in milder cases. The Care4BrittleBones Foundation initiated this project to develop a set of global outcome measures focusing on respiratory-related issues i...

Mar 6th, 2018 - Bisphosphonate therapy is the mainstay of pharmacological intervention in young people with skeletal fragility. The evidence of its use in a variety of conditions remains limited despite over three decades of clinical experience. On behalf of the ...

Mar 17th, 2023 - This protocol seeks to formalize the application of accepted diagnostic and therapeutic measures in the study of individuals with known or suspected bone-related connective tissue disorders, including Osteogenesis Imperfecta and melorheostosis. It...

Mar 9th, 2023 - The primary objective of this study is to evaluate the pharmacokinetics (PK) profile following multiple subcutaneous (SC) doses of romosozumab in children and adolescents with Osteogenesis Imperfecta (OI).

Mar 7th, 2023 - The duration of the study for all participants will be approximately 29 weeks: Up to 5 weeks from initiation of screening to dose administration Treatment on Day 1 Follow-up and observation of safety and PD for 24 weeks Final study visit at Week 24

Mar 6th, 2023 - Participants in Phase 2 will be randomized 1:1 to receive low dose or high dose setrusumab. Participants will continue receiving their assigned dose until the selected dosing strategy is determined for the remainder of the study. Phase 2 participa...

Feb 21st, 2023 - We propose a longitudinal study of the natural history of types III and IV osteogenesis imperfecta for children age birth to 30 years. A consistent objective throughout this study is to obtain a comprehensive assessment of the natural history and ...

Mar 29th, 2022 - Everyone can benefit from good oral hygiene, but people with cancer need to pay particular attention to their dental health because of side effects associated with certain treatments. Osteonecrosis of the jaw (ONJ) involves dead bone in the jaw ...

Feb 28th, 2022 - NEW YORK (Reuters Health) - In adults with osteogenesis imperfecta (OI), a single administration of fresolimumab, a pan-anti-TGF-beta neutralizing antibody, improved bone mass and turnover in a phase 1 study. Currently, there is no specific therap...

Dec 5th, 2020 - University of Pennsylvania's Abramson Cancer Center Established in 1973 as the University of Pennsylvania’s Cancer Center and subsequently renamed in 2002, the Abramson Cancer Center is a world leader in research, patient care, and education. ...

Jul 14th, 2020 - NEW YORK (Reuters Health) - Fetal gene and stem-cell therapies are emerging as treatment options for select conditions, according to a new review. "Fetal cellular and gene therapies are feasible and primed to become viable treatments for a number ...

Aug 8th, 2018 - The OIF will host its biennial national conference in Baltimore July 13-15, 2018. The program will feature sessions on medical care and practical living, forums with leading experts in osteogenesis imperfect care and research, and other opportunit.